ASSNAC: a novel treatment of oxidative stress induced by reactive oxygen

The Invention ASSNAC, S-allymercapto-N-acetylcysteine, is a small bi-functional molecule that up-regulates cellular glutathione levels, the major cellular anti-oxidant. ASSNAC dissociates in peripheral tissues, slowly releasing s-allylmercaptan and NAC. s-allylmercaptan, the thiol-active component of allicin, induces the expression of oxidative stress-related genes and glutathione biosynthesis. NAC, N-acetylcysteine is a food supplement aimed to supply cells with cysteine, a precursor for glutathione biosynthesis and its concentration regulates glutathione biosynthesis rate.

By its duel action, ASSNAC will provide tissues with both induced enzyme and substrate level for glutathione biosynthesis. Thus, ASSNAC may be useful for the treatment of diseases like atherosclerosis, diabetes type 2 and neurodegenerative diseases, which are associated with oxidative stress induced by reactive oxygen species
Potential Applications Atherosclerosis Type 2 Diabetes Neurodegenerative diseases (AD, ALS, PD)

Advantages bioavailable non toxic
Stage ASSNAC has been demonstrated to up-regulate cellular glutathione in vascular endothelial cells in culture and to protect these cells from oxidative stress Patent provisional application 60/915,741, filed may 23, 2007

Inventor(s): Naphtali Savion

Type of Offer: Licensing



« More Pharmaceutical Patents

---